INTERNATIONAL PATENT: ALENTIS THERAPEUTICS AG FILES APPLICATION FOR "CLAUDIN-1/EGFR BISPECIFIC ANTIBODIES FOR TARGETED DEGRADATION"

GENEVA, March 23 -- ALENTIS THERAPEUTICS AG (Hegenheimermattweg 167AAllschwil4123 Basel) filed a patent application (PCT/EP2025/075930) for "CLAUDIN-1/EGFR BISPECIFIC ANTIBODIES FOR TARGETED DEGRADATION" on Sep 11, 2025. With publication no. WO/2026/057723, the details related to the patent application was published on Mar 19, 2026.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): ELSON, Greg (c/o Alentis Therapeutics AGHegenheimermattweg 167AAllschwil4123 Basel), ROUSSEAU, Francois (c/o Alentis Therapeutics AGHegenheimermattweg 167AAllschwil4123 Basel), TOSO, Alberto (c/o Alentis Therapeutics AGHe...